Medtronic PLC (NYSE:MDT) late Wednesday announced that the US Food and Drug Administration (FDA) has approved its PulseSelect Pulsed Field Ablation (PFA) system for the treatment of two heart conditions, paroxysmal and persistent atrial fibrillation, which can cause stroke or heart failure.
The medical technology company said its PFA is used for ablation procedures that treat atrial fibrillation using small burns or freezes to cause some scarring on the inside of the heart to help break up the electrical signals that cause irregular heartbeats.
Medtronic noted it is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
The company added that commercialization of the PulseSelect PFA system will start in early 2024.
Shares of Medtronic rose nearly 1% in pre-market trading on Thursday and have gained 5% year to date.